Call: +919821618106 goral@indonipponivf.com Book an Appointment
Circular teal and navy emblem logo for Indo Nippon IVF Indo Nippon IVF

Pre-implantation genetic screening: benefits and limitations

Pre-implantation genetic screening is now more commonly called pre-implantation genetic testing for aneuploidy, or PGT-A. It is used alongside IVF to examine embryos for chromosome differences before an embryo transfer. For some patients, this information can help the fertility team decide which embryo may have the strongest chance of implantation and ongoing pregnancy.

The test can be relevant to people who have experienced repeated miscarriage, several unsuccessful IVF cycles, or age-related changes in egg quality. It may also be discussed when a patient wants additional information about embryo chromosome status. However, PGT-A is a screening tool, not a guarantee of pregnancy, a replacement for prenatal testing, or a way to identify every possible genetic or developmental condition.

Patients travelling from Australia to Mumbai may compare treatment costs, laboratory capability, waiting times and continuity of care. Someone from Melbourne, Brisbane or Perth may need to coordinate appointments, medication, blood tests and travel around work and family commitments. A clear plan with an IVF specialist is essential before deciding whether embryo testing is appropriate.

What the test examines

During an IVF cycle, eggs are collected and fertilised in a laboratory. The resulting embryos are cultured for several days, usually until they reach the blastocyst stage. A small number of cells are then removed from the outer layer of the embryo, known as the trophectoderm. The embryo is generally frozen while the laboratory analyses the sample.

PGT-A looks for an abnormal number of chromosomes, a condition called aneuploidy. An embryo with the expected chromosome number is described as euploid, while an embryo with an extra or missing chromosome may be classified as aneuploid. Some results are reported as mosaic, meaning the sample contains a mixture of cells with different chromosome findings.

PGT-A should be distinguished from PGT-M and PGT-SR. PGT-M is designed for a known single-gene condition, such as cystic fibrosis or Huntington’s disease, when the genetic change in a family has been identified. PGT-SR assesses structural chromosome rearrangements. The appropriate test depends on personal and family history, previous test results and specialist genetic counselling.

The process involves several stages and cannot be added casually to every IVF cycle. It requires enough embryos to biopsy, a suitable laboratory, reliable genetic analysis and a plan for frozen embryo transfer. The clinic should explain how samples are handled, how results are reported and what happens if no embryo receives a clearly favourable result.

Possible benefits for selected patients

One potential advantage is improved embryo selection. If several blastocysts are available, PGT-A may provide extra information that helps the clinical team prioritise embryos with a chromosome profile associated with a higher likelihood of implantation. This can be particularly meaningful for patients who have a limited number of transfer opportunities or who wish to reduce the chance of transferring an embryo likely to have a major chromosome abnormality.

Aneuploidy becomes more common as egg age increases, although age is not the only factor affecting embryo development. For some older IVF patients, screening may help explain why embryos have failed to implant or why miscarriages have occurred. It may also reduce the number of embryo transfers needed to achieve a pregnancy in some circumstances, though this outcome is not guaranteed.

For people who have had recurrent pregnancy loss, embryo chromosome testing can offer information that may guide discussions with a fertility specialist. It is important to identify other possible causes as well, including uterine factors, sperm-related considerations, hormonal conditions and clotting or immune issues where clinically relevant. PGT-A does not diagnose every cause of miscarriage.

The value of testing can also depend on how many embryos are created. A patient with several good-quality blastocysts may receive more practical benefit from embryo ranking than someone who produces one embryo or no blastocysts. A reputable clinic will discuss the likely benefit in the context of ovarian reserve, age, sperm factors, previous treatment and the couple’s reproductive goals rather than presenting genetic testing as a universal solution.

Limitations and areas of uncertainty

PGT-A examines a few cells from the embryo’s outer layer, not every cell that will form the pregnancy. This sampling method can produce a result that does not perfectly represent the inner cell mass, which develops into the fetus. Mosaic results can therefore be difficult to interpret. Some mosaic embryos may lead to healthy births, while others may have reduced implantation potential or require careful genetic counselling.

A result labelled euploid does not guarantee implantation, a healthy pregnancy or a healthy child. Embryo quality, uterine receptivity, sperm and egg factors, laboratory conditions and chance all influence outcomes. PGT-A also does not detect every genetic disorder, birth defect, developmental condition or future health problem. Standard antenatal screening and diagnostic testing remain important after pregnancy.

There is also a risk that testing may leave patients with no embryo suitable for transfer. Embryos may fail to develop to the biopsy stage, produce an inconclusive result or be classified as abnormal. For someone with a small number of embryos, the test may provide little selection advantage while adding cost, time and emotional pressure. The biopsy and freezing process are highly established, but no laboratory procedure is entirely risk-free.

Patients should ask whether PGT-A improves the live birth rate for people with a similar profile, rather than focusing only on laboratory accuracy. Evidence can vary according to age group, embryo numbers and clinic practice. The phrase “genetically tested” can sound reassuring, but it should never be treated as a promise. Genetic counselling is particularly important when a mosaic or complex result is reported.

Considerations for patients in Australia

Australian patients often begin with a GP referral, a fertility specialist consultation and investigations that may be arranged through a local clinic. Medicare rebates may apply to some eligible fertility services, but out-of-pocket costs differ significantly between providers, states and treatment plans. PGT-A, embryo storage, medications, travel and accommodation can involve additional expenses, so a written estimate is worth requesting before treatment begins.

Rules and practical arrangements can vary across Australia. IVF and donor programs operate within state and territory frameworks, and surrogacy has separate requirements that differ between jurisdictions such as New South Wales, Victoria, Queensland and Western Australia. Patients considering donor eggs, embryo transport or surrogacy should obtain advice relevant to their home state before making commitments overseas.

For someone travelling from Australia to India, coordination is a major part of care. Blood tests and ultrasound scans may be completed in Australia and shared with the overseas fertility team, while egg collection and embryo transfer usually require time in Mumbai. Ask who will review results after returning home, how urgent concerns will be handled across time zones and whether a local obstetrician or fertility doctor will receive the records.

Clinic experience and communication matter as much as advertised technology. Patients can review clinic updates to understand the provider’s areas of work, then ask direct questions about embryology staff, biopsy methods, accreditation, sample transport, embryo storage and reporting of mosaic findings. A video consultation before booking travel can help clarify whether PGT-A is recommended or simply available.

The language used in an Australian consultation may also differ from the language used overseas. Terms such as “egg collection”, “cycle”, “bulk-billed” and “out-of-pocket” are familiar locally, while an international clinic may discuss “oocyte retrieval”, “retrieval charges” or package pricing. Patients should ask for every cost and clinical step in plain English, including what happens if the cycle is cancelled or no embryo is transferable.

Practical points to discuss before testing

A sound decision comes from combining medical evidence with personal priorities. Some people value the possibility of reducing avoidable transfers, while others prefer to limit additional procedures and costs. Neither approach is automatically right. The decision should reflect the patient’s age, embryo numbers, previous history, emotional wellbeing and available budget.

Useful questions for a consultation include:

The answers should be documented in an individual treatment plan. Patients should also ask how long results take, whether embryos can be transferred in a future cycle and whether a second opinion is available for complex findings. A clinic that explains uncertainty clearly is usually better placed to support informed consent than one that presents testing as a simple guarantee.

Indo Nippon IVF provides fertility care for patients seeking IVF, ICSI, donor egg treatment, embryo transfer and related reproductive services. Its specialist team can discuss whether embryo chromosome screening fits a proposed treatment pathway and how care may be coordinated for patients travelling from Australia to Mumbai.

If you are considering PGT-A, arrange a consultation before booking flights or starting medication. Bring previous IVF reports, miscarriage records, genetic test results and a list of current medicines. A specialist can assess your circumstances, explain realistic benefits and limitations, and help you decide whether genetic screening is a sensible part of your family-building plan.